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Abstract
Various tools and techniques are being used for the diagnosis of cancer, but not
a sole technique provides powerful result at the very early stages of cancer. This
provides the need for type of tools which could detect cancer at early stages so that
survival rate could be augmented. There are various diagnostic ways to identify
cancer, but in each case, there are always circumstances to compromise on the
sensitivity. In this framework, a new and more advanced approach of diagnosis for
cancer is microRNA (miRNA). miRNAs are conserved regions among humans and
animals, and their synthesis takes place in the nucleus and cytoplasm. There are
several types of microRNAs that could be upregulated and downregulated in vari-
ous cancers. A cancer cell could be identified by measurement of the expression
pattern of miRNA. By examining the expression level for different types of cancers,
miRNA can be used as biomarker for early detection of cancer in human beings.
Keywords: microRNA, cancer biomarker, diagnostic, colorectal, upregulation,
downregulation, breast cancer, cervical, liver, prostate
1. Introduction
MicroRNAs (miRNAs) are a small, non-coding, single-stranded RNA consisting
of around 22 nucleotides [1]. More than 3% of the human genome (gene portion)
encodes for microRNA, and their number is around 1000 [2–4]. This small RNA can
regulate gene expression posttranscriptionally [5–7]. This small RNA can regulate
gene expression posttranscriptionally by binding to its cognate RNA target at the 30
untranslated region (UTR) [8–11]. A small microRNA was discovered for the first
time in C. elegans and is encoded by the Lin-4 gene [12] providing evidence for its
evolutionary conservation. This conserved microRNA was found to be involved in
many important biological processes including cell proliferation, growth, apoptosis,
etc. [13, 14], and many cell-based factors have been known to regulate its expres-
sion [15]. The genes transcribing the miRNA are considered to belong to the set of
tumor suppressor genes, and the serum level of miRNA can be detected [16, 17].
There are certain miRNAs that can behave as either oncomiRs (whose expression
can cause the cancer) or tumor suppressor depending on the context “Several
miRNAs cannot be clearly and unequivocally categorized as tumor suppressors or
oncomiRs because data in our hands are quite intricate and conflicting since they
could act as tumor suppressors in one scenario or as oncomiRs in the other” [18].
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2. Synthesis/biogenesis of miRNA
Synthesis of miRNA takes place in the nucleus as well as in the cytoplasm.
Genes encoding miRNAs are present in the form of a cluster and contain introns
(Figure 1). These genes are transcribed by polymerase II with the generation of the
primary precursor pri-miRNA. This precursor miRNA consists of a 30 poly-A tail
and a 50 end cap [19, 20] with a stem-loop structure. RNase 3 Drosha cleaves this
structure with the help of its Pasha cofactor DGCR8. This resultant cleaved, pre-
cursor structure is known as pre-miRNA and consists of 70–90 nucleotides [21].
This 70 nt precursor is exported to the cytoplasm by Exportin-5.
In the cytoplasm, the whole pri-miRNA is recruited by a RNA-induced silencing
complex (RISC) and is converted into mature miRNA. These are mediated by an
RISC leaching complex (RLS), which is basically a multiprotein complex and con-
sists of a double-stranded RNA domain protein (DICER), tar RNA-binding protein
(TARB), and the Ago 2 protein. The RNAse 3 DICER along with its cofactor yields
duplex miRNA (19–25 nucleotide duplex miRNA with 2 nucleotide overhangs at
each 30end). During the process of cleavage, two strands are formed, namely, a
functional and a passenger strand. The functional strand along with the Ago protein
(RISC) is involved in gene silencing function, while the passenger strand is
degraded due to its instability. This miRISC incorporates one strand of miRNA
(functional strand and guide strand) so that it takes the guidance from this complex
to target mRNA (complementary) for its degradation or inhibition at the transla-
tional level [22]. miRNA is processed in the cytosol and transported to the blood.
It is resistant to degradation because it is carried by complexes of lipoprotein
inclusions [23] or in the form of exosomes [24, 25].
3. Mechanism of action
The mechanism of action of microRNA is such that it binds to its partial
complementary sequence in the target mRNA (that codes for protein). Hence, the
expression is repressed (Figure 2) and no product is synthesized [7].
In another scenario, the microRNA may bind to the complementary sequence of
target mRNA that codes for protein and initiates RNA-mediated gene silencing,
with the resultant cleavage of the target RNA (Figure 3) [26].
Figure 1.
Biogenesis of microRNA.
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4. Diagnosis of cancer
There are reported differences in the expression pattern of miRNA in normal
and cancer cells [27]. Some miRNAs are overexpressed, while the others are
downregulated in different kinds of cancers [28]. Due to its small size and resistance
to RNase-mediated degradation, they have the potential as powerful biomarkers for
cancer diagnosis [29]. miRNA expression is involved with the rearrangement of
chromosomes, methylation of the promoter region, and transcriptional regulation.
miRNA-mediated aberrations in one or more of these processes can culminate in
alterations in protein and mRNA expression [30].
5. Types of miRNA and cancer according to organs
Different miRNAs are involved in different types of cancers:
5.1 Breast cancer
Breast cancer is the most prevalent form of cancer in women. Among 12.7
million cancer cases globally, breast cancer is most frequently diagnosed, that is, 23
and 14% deaths due to breast cancer have been reported [1, 31]. The alarmingly
increasing mortality data coupled with increases in relapses warrants an improved
molecular understanding of the etiology and mechanistic details that contribute to
the chemoresistance. There are four subtypes (intrinsic) of breast cancer. These are
ErbB2+ (epidermal growth factor receptor 2-positive (also called HER2)), luminal A
Figure 2.
Mechanism of action of miRNA.
Figure 3.
Mechanism of miRNA.
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(hormone receptor positive for estrogen and progesterone, HER2), luminal B (hor-
mone receptor positive for estrogen and progesterone and positive or negative for
HER2), and basal like (hormone receptors negative for estrogen, progesterone, and
HER2) showing its heterogeneity. Many of the microRNAs play a role in the inhibi-
tion of breast cancer. The upregulation of miR-21 (Table 1) results in the increased
expression of BCL-2 protein and chemoresistance in breast cancer [38]. MiR-125b
shows the resistance to chemotherapeutic agents 5-fluorouracil, and it has higher
expression in the patients that are nonresponsive to this agent (Table 2). Many
promote the prognosis of breast cancer by targeting the tumor suppressor at
the gene level and activating the transcriptional factors that are oncogenic in
nature [32, 38].
The Rab protein is a member of the Ras superfamily (Figure 4). This protein is a
G-protein-coupled receptor and is involved in many cellular processes including
fusion, budding, synthesis of vesicles, and motility [55]. A member of the Rab class
is Rab11a, and this protein has many functions including cellular migration and
phagocytosis [56]. In breast cancer there is overexpression of Rab11a protein [57]
and is regulated by miRNA 320a. This miRNA can downregulate Rab11a protein,
thereby mediating the inhibition of breast cancer progression.
MiR-320a has an important role in tumor suppression [58] and can be a bio-
marker for breast cancer. This miR-320a results in a 15% increase of cells in G0/G1,
Sr. no. MicroRNAs Potential targets Function Ref.
1 miR-10b Homeobox D10 Promotes cellular invasion,
migration, and metastasis by
targeting the RhoC
[32]
2 miR-21 Programmed cell death
protein 4, hypoxia-
inducible factor-1α
Promotes cellular invasion,
metastasis, epithelial-to-
mesenchymal transition and
migration
Phosphatase and tensin
homolog, programmed cell
death protein 4,
tropomyosin 1
Promotes cellular invasion [33]
Metalloproteinase inhibitor
3
Promotes cellular invasion [34]
3 miR-155
(chemosensitive
determinant by
targeting the
FOXO3)
Suppressor of cytokine
signaling 1
Promotes cell proliferation and
growth
[35]
Tumor protein p53
inducible nuclear protein
Promotes cell proliferation [36]
Forkhead box protein O3 Promotes cell proliferation and
cell survival
[37, 38]
4 miR-373 CD44 (inversely
correlated)
Promotes cellular invasion and
migration
[39]
Promotes cellular invasion and
metastasis
[40]
5 miR-520c Promotes cellular migration,
invasion, and metastasis
[39]
Meta-analysis or Cochrane reviews documenting the involvement of a specific miRNA or a battery of miRNAs
contributing to relapse or recurrence can be displayed as a separate table for each of the cancers.
Table 1.
MicroRNAs upregulating the breast cancer.
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and the population of cells in the S phase is decreased. Apart from the G0/G1 cell
cycle arrest, miR-320a also increases the activity of caspase resulting in the induc-
tion of apoptosis [59]. The potential target of miR-20 is Rab11a; it has two binding
sites at the 30UTR region for miR-320a and can mediate its posttranscriptional
repression. This protein is also necessary for the activation of Akt via phosphatidy-
linositol-4-kinase (PI4K3) in breast cancer—a pro-survival signal [60]. Further,
overexpression of Rab11a protein results in the reversal of cell cycle arrest and
apoptosis mediated by miR-320a by targeting the MTDH at 30UTR [61]. The gene
coding for the Rab coupling protein (RCP) (a Rab11-FIP1C (Rab coupling protein))
Sr. no. MicroRNAs Potential targets Function Ref.
1 miR-125b Erythropoietin, erythropoietin
receptors (positive correlation with
ERBB2/HER2 expression)
Inhibition of cellular
differentiation and
proliferation
[41]
Glutamyl aminopeptidase or
aminopeptidase A, casein kinase 2-
alpha, cyclin J, multiple EGF-like
domains 9
Inhibition of cellular
proliferation
[42]
Receptor tyrosine-protein kinase
erbB-2 (human epidermal growth
factor receptor 2) (induction of miR
cause the downregulation of ERBB2/
ERBB3)
Inhibition of invasion and
migration
[43, 44]
2 miR-205 High-mobility group box 3 gene Suppression of invasion and
proliferation
[45, 46]
3 miR-17-92 Mitogen-activated protein kinase
kinase kinase 2
Promotes the antitumoral
activity of natural killer
cells and reduction in
metastasis
[47]
4 miR-206 Cyclin D2, connexin 43 Reduction in invasion,
migration, and metastasis
[48]
5 miR-200 Zinc finger E-box binding homeobox
1/2, snail family zinc finger ½
Reduction in tumor growth,
EMT through E-cadherin,
and metastasis
[49]
6 miR-146b Nuclear factor kappa B, signal
transducer, and activator of
transcription 3
Reduction in survival and
metastasis via interleukin 6
[50]; Not
referenced
7 miR-126 Insulin-like growth factor-binding
protein 2, c-Mer tyrosine kinase,
phosphatidylinositol transfer
protein, cytoplasmic 1
Reduction in angiogenesis
and metastasis
[51]
8 miR-335 SRY-related HMG-box 4, tenascin C Suppression in migration
and metastasis
[52]
9 miR-31 Ras homolog gene family Targets various steps of
metastasis and invasion for
inhibition
[38]
WAS protein family, member 3, Ras
homolog gene family
Reduction in the metastasis
and progression of cancer
[53]
WAS protein family, member 3 Reduction in the metastasis
and progression of cancer
[54]
Table 2.
MicroRNAs downregulating the breast cancer.
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is amplified in breast cancer and aids in the sorting of epidermal growth factor
receptor (EGFR) [62, 63]. For the metastasis or migration of cancer, the cell critical
factor is RCP which mediates this effect via cell surface integrin alpha-5-beta-1
demonstrating that Rab11a is a protein that is involved in the metastatic or invasive
phenotype of breast cancer [64, 65].
5.2 Colorectal cancer
Colorectal cancer is the third most common cancer around the world. The
incidence rate is increased up to 6% [66]. Survival rate can increase to 90%, if it is
diagnosed at an early stage. Survival rate is inversely proportional to the stage of
cancer [67].
In a study, the cluster of miR-17/miR-92 (chromosomal region 13q31.1 with
miR-20a as one of its members). The region encompassing this cluster is under the
regulation of the oncogenic Myc transcriptional factor and TGF-β [68, 69].
Overexpression converts a benign tumor to colorectal cancer [70].
Mir-20 acts as a potential colorectal cancer cell biomarker [71]. Induction of
miR-20-mediated EMT is a critical factor contributing to the increases in tumor cell
migration, metastasis, E-cadherin downregulation, and upregulation of matrix
metalloproteinases (Figure 5) [72, 73]. This microRNA can cause a delay in TGF-β-
mediated G1/S transition. However, cell cycle progression occurs due to an
inactivating mutation in this pathway [74]. Normal TGF-β-mediated signaling can
be a cytostatic response and inhibit tumorigenicity in colorectal cancer cells [75].
Figure 4.
MicroRNA and breast cancer.
Figure 5.
MicroRNA and colorectal cancer.
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miR-20 may be degraded by a bacterial strain that is dominant in the lumen of the
bowel of colorectal patients. Hence, expression of miR-20a is reduced in patients
having colorectal adenoma [76–78].
In another study, miR-34a modulates EMT and MET processes. There is
methylation in CpG islands (cancer specific), and these are repressed by
IL-6/STAT3 pathway which is mediated by interleukin-6 receptors (IL6R) and
inactivation of TP53. This results in downregulation of miR-34a [79]. miR-34a
inhibits SIRT and activates TP53. A positive feedback loop has been suggested
between miR-34a (Table 3) and TP53 [81]. In many cancers, TP53-inducible
microRNA is miR-34a [82].
In another study, miR-200 is downregulated in primary colorectal cancer
(invasive stage) correlatable with the disruption of the basement membrane [83].
The miR-200 family consists of five members and is encoded in two clusters. One
cluster is present on chromosome 1 and encodes for miR-200a, miR-200b, miR-
200c, and miR-141. The other cluster is present on chromosome 12 and encodes for
miR-141. The potential target of miR-200 family is ZEB1/ZEB2 which is a repressor
of CDH1 (Table 4). Expression of all members of this family can be repressed
following methylation of CpG islands in the regulatory region of their genes
[84, 85]. Strong expression of miR-200 results in metastatic colorectal cancer [83].
Another study shows that miR-155 and miR-21 are overexpressed in colorectal
cancer [86]. In another study involving colorectal cancer patients, the expression of
miR-195 and miR-497 is reduced [87].
5.3 Cervical cancer
Cervical cancer is the most common cause of death among women in the devel-
oping countries [88, 89]. Cervical cancer can cause the death of 270,000 women per
year [90]. Human papillomavirus (HPV) is the causative agent, with the E6 and E7
proteins targeting p53 and pRb, respectively [91].
Sr. no. MicroRNAs Potential target Function
1 miR-185 Ras homolog gene family, member
A, and cell division control protein
42 homolog
Reduction in the proliferation, induction
of cell cycle arrest at the G1 stage, and
promotion of apoptosis
2 miR-192 cyclin-dependent kinase inhibitor 1 Regulating the p53
3 miR-215
4 miR-34a Tumor suppressor p53 Modulate the EMT transition
Table 3.
MicroRNAs suppressing the colorectal cancer [80].
Sr. no. MicroRNAs Potential target Function
1 miR-130a Mothers against decapentaplegic
homolog 4 (SMAD4)
Enhances the cell proliferation and
migration
2 miR-301a
3 miR-454
4 miR-200 Zinc finger E-box-binding homeobox ½ Promotes metastasis
Table 4.
MicroRNAs promoting the colorectal cancer [80].
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Several miRNAs are upregulated and downregulated during cervical cancer
(Table 5). miR-135b is a biomarker for cervical cancer. Suppression of this bio-
marker results in the inhibition of cell growth.
Downregulation of miR-135b results in the percentage of G1 cells with a con-
comitant decrease in those in the S phase. The expression of cyclin-dependent
kinases (p27 and p21) is increased and that of cyclin D1 is decreased. Cyclin D1
(nuclear protein) is responsible for the regulation of cells (proliferating) that are at
the G1 phase of the cell cycle [72, 73].
There seems to be an inverse relationship between miR-135b and FOXO1 pro-
tein. When FOXO1 protein is downregulated, cervical cancer is promoted. When
FOXO1 protein is expressed, then there is an increase in the p27 and p21 expression
with a decrease in cyclin D1 level and cell cycle is arrested [95, 96]. So, when miR-
135 is downregulated, FOXO1 is upregulated with the resultant inhibition of cell
growth (Figure 6).
In cervical cancer, miR-196a is upregulated and its targets are p27Kip and
FOXO1. It promotes the transition of cells from G1 phase to S phase, enhances the
cellular proliferation by involving the PI3K/Akt pathway, and is involved in
tumorigenesis [97].
In one study, miR-10a is overexpressed in cervical cancer (Long et al., 2012;
[28]). The target of miR-10a is transmembrane protein type 1 close homolog of L1
(CHL1) that is downregulated. A decrease in CHL1 protein dysregulates PAK and
MAPK pathways resulting in increases in cell growth followed by migration and
invasion [98].
In another study, miR-21 is upregulated in cervical cancer, and it is located at the
17q23.21 locus (Table 6). The pri-miR-21 is transcribed by the intronic region of
TMEM49 (protein-coding gene). This miRNA targets the p53 and Cdc25 (regulators
of the expression of genes), TPM1 and RECK (suppressing the metastasis), and
PTEN and PDCD4 (inducing the apoptosis of metastasized cell). Hence, decreases
in this miRNA can result in the PDCD4 gene providing signals for the activation of
the RAS pathway. This activation, in turn, activates the transcription factor AP-
Type of
miRNA
Function Ref.
miR-491-5p Downregulated; suppress cervical cancer by telomerase reverse transcriptase and
regulate the PI3K/AKT pathway
[92]
miR-142-3p Inhibit the proliferation of cell Frizzled_7 receptor (FZD7) [93]
miR-142-3p Inhibit the growth of cell via downregulation of its FOXM1 target [94]
Table 5.
AmiRNA involved in cervical cancer.
Figure 6.
MicroRNA and cervical cancer.
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1gene. This AP-1 binds to a specific site on the promoter of miR-21 and as a result
miR-21 gene is transcribed [99], thereby providing a plausible mechanism for a
positive feedback loop.
It was reported that miR-886-5p targets and negatively regulates Bax gene
expression via inhibition of translation, and hence, this form of control may be
significant for the development of cervical cancer. When there is a death signal, the
proapoptotic protein coded by Bax gene is inserted into the outer membrane of
mitochondria. As a result, cytochrome C is released, and the initiator caspase-9 is
subsequently activated with the initiation of apoptosis (Table 7) [91].
5.4 Liver cancer
Liver cancer is rising very rapidly globally with aflatoxins also contributing to its
etiology. Specific miRNA may be expressed in the case of liver cancer. One of the
Sr. no. MicroRNAs Potential targets Function Ref.
1 miR-196a Binds to the 30UTR of p27Kip and
FOXO1 and inhibits their
translation
Increases in cell proliferation and
tumorigenesis
[97]
2 miR-10a Has an inverse relation with the
expression of close homolog of L1
(CHL1) transmembrane protein
type 1—a cell-adhesion protein
Cell growth followed by migration
and invasion
[91]
3 miR-21 Negatively regulates p53 and
Cdc25, TPM1 and RECK, and
PTEN and PDCD4
Enhances the expression of genes
associated with cell proliferation,
metastasis, as well as those involved
in the antiapoptosis effect
[91]
4 miR-886-5p Negatively regulates the Bax gene Dysregulation of the gene involved
in apoptosis (miR-10a, miR-106b,
miR-21, miR-135b, miR-141,
miR146, miR-148a, miR-214, and
miR-886-5p)
[91]
5 miR-20a TNKS2 oncogene is upregulated
(by binding at 30UTR of mRNA of
TNKS2 results in enhanced
translation)
Migration, colony formation, and
invasion
[91]
Table 6.
MicroRNAs activating the cervical cancer.
Sr. no. MicroRNAs Potential target Function
1 miR-143 Target k-Ras, Bcl-2 and Macc1, specifically
downregulation of Bcl-2
Inhibition of apoptosis and
uncontrolled cell proliferation
2 miR-129-5p Downregulates HPV18 E5 and E7 expression
as well as inhibits the translation of SP-1
transcriptional factor
Suppressing the progression of
cervical cancer
3 miR-34a Cyclin E2 and D1, CDK6, E2F3, CDK4, E2F1,
E2F5, P18, Bcl-2, and SIRT1
Aberrations in cell
proliferation and
differentiation—cell
transformation
Table 7.
MicroRNAs suppressing cervical cancer [91].
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miRNA biomarkers in liver cancer is miR-26a. Its expression is reduced in
liver cancer unlike normal hepatic cells, where its expression level is increased [100].
miR-26a and miR-34a cause an increased number of cells in the G1 phase of the
cell cycle, while there is a decrease in the cells in the S phase of the cell cycle. miR-26
causes cell cycle arrest at the G1 phase [84]. In the 30UTR region of cyclins E2 and
D2, there is a conserved binding site for miR-26a. miR-26a binds to these binding
sites and represses the expression of both cyclins (Figure 7). miR-26 causes the
induction of apoptosis in the tumor cells and suppresses hepatic cancer [101].
Kim et al. studied the expression of miR-31 in liver cancer (Table 8). The main
target of miR-31 is CDK2 protein and HDAC2, with these proteins suppressed in the
livers of normal individuals. There is an enhanced expression of CDK2 protein and
HDAC2 in liver cancer. When HDAC2 is suppressed, p21WAF1/Cip1 and p16INK4A are
activated, and positive regulators of the cell cycle (cyclin D1, CDK2, and CDK4) are
suppressed simultaneously [102].
In another study, the expression of miR-9 enhances the formation of tumor
spheres in the liver. The direct target of the miR-9 is PPARA and CDH1 genes and
regulates them via binding to the 30UTR region of these genes. Upregulation of miR-
9 enhances the level of vimentin (mesenchymal marker) and deregulates the CDH1
(Table 9). The transcriptional factor PPARA has been implicated in the metabolic
homeostasis of the liver by regulating the nuclear factor-4 alpha (hepatocyte
HNF4A) gene, which is a tumor suppressor. In liver cancer, miR-9 suppresses the
CDH1 and also suppresses the PPARA at their mRNA level by binding to the 30UTR
of these genes [103].
In one study, there is overexpression of miR-525-3p in liver cancer, and its
potential target is a zinc finger protein (Krüppel C2H2 type family) ZNF395. This
Figure 7.
MicroRNA and liver cancer.
Sr. no. MicroRNAs Potential
targets
Function Ref.
1 miR-26a Cyclin E2 and
D2
The arrest of the cell cycle at G1 phase [84]
2 miR-31 CDK2 protein
and HDAC2
Suppress the positive regulators of cell cycle and
promote those proteins involved in EMT-related
processes
[102]
Table 8.
MicroRNAs suppressing the liver cancer.
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zinc finger protein was originally a transcriptional factor and binds to the promoter
region of the human papillomavirus (HPV). This protein mediates the regulation of
PI3K/Akt pathway and causes the inhibition of cell growth via the induction of
caspase-3 and the promotion of apoptosis. The expression of miR-525-3p enhances
cell growth and prevention of apoptosis [104].
5.5 Prostate cancer
In countries in the West, prostate cancer is a more prevalent form of cancer
among males with an increasing incidence rate [105]. Prostate cancer is the result of
undesirable genomic alteration [106, 107]. CD9 is inactivated during prostate can-
cer and may cause its progression [108].
In the prostate cancer, serum level of miR-141 is elevated [109]. So it acts as the
biomarker of prostate cancer. In the progression or repression of prostate cancer,
miR-141 function is understood poorly [110]. One other study is done by Waltering
et al. in which miR-141 is castrated and results in upregulation and activation
(Figure 8). This causes the LNCaP cell growth to increase. This miRNA is also
involved in the regulation of signaling of the androgen. This androgen has a crucial
role in the growth of prostate cancer (castration-resistant and androgen-
dependent). So it may be involved in the progression of prostate cancer [111, 112].
In a study involving prostate cancer, miR-888 was found to be upregulated. Its
target is the tumor suppressors SMAD4 and RBL1. Binding of this miRNA to the
30UTR causes their downregulation. RBL1 is the member of the RB (retinoblastoma)
family and blocks the progression of cells at the G1-S phase following its binding
and inhibition of the transcription factor E2F. SMAD4 protein binds to SMAD
receptors and transduces the signal initiated by TGF-β/BMP ligands in order to
regulate differentiation and cell growth [113].
In another study, there is the downregulation of miR-23a, b (Table 10). There is
upregulation of the-Myc gene which causes the repression of these miRNAs at the
transcriptional level. Mitochondrial glutaminase protein is expressed in the prostate
Figure 8.
miRNA and prostate cancer.
Sr. no. MicroRNAs Potential targets Function Ref.
1 miR-9 Influences the PPARA/
CDH1pathway
Suppress the tumor suppressor [103]
2 miR-525-3p Downregulates ZNF395 Enhances cell growth and prevent apoptosis [104]
Table 9.
MicroRNAs activating the liver cancer.
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cancer cells. Consequently, glutamine catabolism is increased, providing a growth
advantage to the cancer cells [114].
In another study, miR-34a is suppressed in prostate cancer. The target of miR-
34a is deacetylase sirtuin (SIRT1) and cyclin-dependent kinase 6 (CDK6). CDK6
regulates cyclin D, which, in turn, regulates cell cycle progression and G1-S phase
transition, while p53 protein-dependent apoptosis is regulated by SIRT1 via
deacetylation and stabilization of p53. The target of the p53 gene is miR-34a. It is
suggested that there is a positive feedback loop in which SIRT1 mediates the acti-
vation of miR-34a via stabilization of p53 and induces the apoptosis and blocks the
cell cycle transition. This activation of p53 causes the upregulation of miR-34a
which in turn suppresses the SIRT1 (Table 11) [114].
5.6 Lung cancer
The leading cause of death around the world is lung cancer by tobacco smoke.
This environmental lifestyle-related factor may cause undesirable epigenetic and
genetic modifications [115]. The key role in lung cancer is the alteration and muta-
tion in tumor suppressor genes (p53 and RB/p16pathway) and less frequent is the
genetic alteration of FHIT, K-ras,MYO18B, and PTEN [116].
Five miRNAs were differentially expressed in lung cancer tissues, and these
include miR-21, miR-155, miR-145, miR-17-3p, and hsa-let-7a-2. Specifically, hsa-
miR-155 levels were increased, while that of hsa-let-7a-2 was downregulated [117].
There is a functional interaction of let-7 with the Ras as a target gene is
overexpressed associated with protein kinase and resulting intracellular pathway of
signaling [118]. The molecular mechanism is unclear involving miRNA in lung
cancer. Alteration in the somatic genes resulted in the defective miRNA expression
in lung cancer. This reduced expression of miRNA (has-let-7a-2) in the lung cancer
is due to epigenetic modification and results in the silencing of tumor suppressor
gene and many others (Figure 9) [119, 120]. The expression of hsa-miR-21 is
upregulated in cancer cell and causes the inhibition of product of gene which
initiates apoptosis and causes lung cancer [121]. In a report miR-1792 cluster is
overexpressed in the lung cancer. This cluster consists of six miRNAs.
Sr. no. MicroRNAs Potential targets Function Ref.
1 miR-141 LNCaP cells Promote cell growth
Decreased growth in response to anti-miR-
141 treatment
[112]
2 miR-888 Downregulates SMAD4
and RBL1
G1-S phase transition [113]
Table 10.
MicroRNAs activating the prostate cancer.
Sr. no. MicroRNAs Potential targets Function
1 miR-23a,b Glutaminase protein (indirect) Glutamine catabolism
2 miR-34a SIRT1 and CDK6 Progression of cell cycle, G1-S phase
transition, and antiapoptosis
Table 11.
MicroRNAs suppressing the prostate cancer [114].
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This cluster in lung cancer is transactivated via MYC and members of the E2F
family. The direct target of this cluster is HIF-1α. Upregulation of MYC causes the
downregulation of HIF-1α and affects proliferation of cell in normoxia without
affecting the hypoxic condition. Overexpression of this cluster causes knockdown
of retinoblastoma gene and results in the formation of reactive oxygen species.
Another direct target of this cluster is RAS-related protein 14 (RAB-14), and it is
downregulated by this cluster and results in the initiation and development of
cancer [122].
In another study, miR-21 is upregulated in the lung cancer. Its direct target is
tumor suppressor gene PTEN that is repressed by overexpression of miR-21
(Table 12), which results in cell growth enhancement and non-small cell lung
carcinoma invasion [123]. miR-21 is upregulated by RAS via PI3K and RAF/MAPK
pathways [122].
In another study, miR-34 is downregulated in the lung cancer. This miRNA is
directly regulated by p53 and regulates the apoptosis and arrest of the cell cycle in
cancer [81].
The miR-34/miR-499 is downregulated in lung cancer and its direct target is E2F
and p53 (Table 13). Both miRNAs suppress the E2F and upregulate the p53 via
SIRT1 so cell growth is increased [124].
The miR-15/miR-16 is downregulated in lung cancer. There is upregulation of
cyclin D1 with the downregulation of miR-15/miR-16. The overexpression of
miR-15/miR-16 causes the arrest of the cell cycle at G1 phase [122]
Figure 9.
miRNA and lung cancer.
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5.7 Gastric cancer
The second malignancy that is widely prevailed is the gastric cancer which
results in 12% deaths around the world [125]. Gastric cancer is the result of a series
of steps. When transforming growth factor (TGF-beta) resistance is developed and
E2F1 is upregulated, then gastric cancer is developed [126, 127].
In gastric cancer, there is upregulation of cluster of miR-106b-25 present on
Mcm gene [128]. The transition of the G1/S phase of the cell cycle is targeted by
Mcm gene. It ensures that DNA is replicated only one time when replication fork is
assembled on the DNA during each cycle [129]. When cells exit from the mitosis,
then expression of cluster of miR-106b-25 is activated by E2F1 (Figure 10) and
gains the reentry in the G1 phase of the cell cycle. The cell cycle inhibitor is
p21 [130].
The cytokine TGF-beta causes the cell cycle arrests by activating p21 and causes
the apoptosis [131]. As this cytokine is activated it causes the downregulation of
miR-106b-25 cluster, reduces the expression of E2F1, causes the cell cycle arrest at
G1/S phase of cell cycle, and causes the induction of apoptosis. The key target of
miR-93 and miR-106b is E2F1 [132]. The key target of miR-25, the biomarker of
gastric cancer, is TGF-beta cytokine [133]. The target of cytokine in mediating the
apoptosis is Bim protein that in turn causes the activation of proapoptotic Bax and
Bad molecules acting as an antagonist of Bcl2 and BclXL antiapoptotic factors
(Figure 11) [134].
Sr. no. MicroRNAs Potential targets Function Ref.
1 miR-34 p53 Regulate the apoptosis and
arrest of cell cycle
[81]
2 miR-34/miR-499 E2F and p53 Cell growth and proliferation [124]
3 miR-15/miR-16 Cyclin D1 The arrest of the cell cycle at
the G1 phase
[122]
Table 13.
MicroRNAs suppressing the lung cancer.
Sr. no. MicroRNAs Potential targets Function Ref.
1 let-7 Ras Protein kinase-associated
signaling pathway
[118]
2 miR-1792 HIF-1α and RAB14 ROS and initiation and
development of cancer
[122]
3 miR-21 PTEN Cell growth enhancement
and invasion
[122]
Table 12.
MicroRNAs activating the lung cancer.
Figure 10.
miR-106b-25 cluster.
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Lim found that miR-196b is upregulated in the gastric cancer (Table 14). This
miRNA is present in chromosome 9 at HOXA cluster. There is a positive association
of expression of miR-196b with the expression of HOXA10. Unmethylation of CpG
islands results in the expression of miR-196b. The HOXA10 expression results in
hematopoietic stem cell proliferation and progenitor cell proliferation leading to the
development of cancer via expression of genes that codes for integrin-β3, TGFβ2,
and dual-specificity protein phosphatase 4 [135].
We studied miR-375 is downregulated in gastric cancer (Table 15). Its expres-
sion in cancer cell causes the decrease in cell viability by downregulation of PDK1
and JAK2 revealing that miR-375 is a tumor suppressor in gastric cancer [136, 137].
In another study, miR-135a is a tumor suppressor in gastric cancer. Upregulation
of miR-135a causes the suppression of gastric cancer via suppression of proliferation
of cell via E2F, metastasis, and EMT. In gastric cancer, lymph node metastasis is
associated with proliferation, metastasis, and EMT which is suppressed by
overexpression of miR135a [138].
Figure 11.
miRNA and gastric cancer.
Sr. no. MicroRNAs Potential targets Function Ref.
1 miR-106b-25 E2F1 Antiapoptosis and cell proliferation [132]
2 miR-196b HOXA10 Progenitor and hematopoietic stem
cell proliferation
[135]
Table 14.
MicroRNAs activating the gastric cancer.
Sr. no. MicroRNAs Potential targets Function Ref.
1 miR-375 PDK1 and JAK2 Decrease the cell viability [136, 137]
2 miR-135a E2F Suppress cell proliferation,
metastasis, and EMT
[138]
Table 15.
MicroRNAs suppressing the gastric cancer.
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5.8 Bladder cancer
In males, bladder cancer is an important malignancy present in two forms that
are muscle invasive and non-muscle invasive (benign) [139]. There are two
microRNAs associated with bladder cancer. They are miR-21 and miR-129 [140].
In the bladder cancer, miR-129 and miR-21 both are upregulated. The direct
target of miR-21 is the tumor suppressor genes that are TPM1 and PTEN
(Figure 12) [141, 142]. The known targets of miR-129 are the genes involved in the
regulation of transcription and processing of miRNA that are TAMTA1 and EIF2CA
[143]. The mir-129’s pathway of death effectors leads to the tumor as its target is
also SOX4 [144].
According to one study, miR-19a is frequently upregulated in the bladder
cancer. The expression of miR-19a is related to PTEN expression (Table 16).
PTEN is a tumor suppressor gene. When miR-19a is overexpressed, it causes the
downregulation of PTEN and increases the cell level of phosphatidylinositol-3,4,5-
trisphosphate in AKT/PKB pathway. When growth factors are released, then the
AKT pathway is initiated and cell growth is increased [145].
Zhang studied that miR-125b is downregulated in bladder cancer. The expres-
sion of miR-135b causes the inhibition of formation of colony and development of
cancer via suppression of E2F3 which is overexpressed in bladder cancer [74].
In another study angiogenesis in the bladder cancer is suppressed by miR-34a
(Table 17). The target of miR-34a is CD44 and causes the suppression of CD44
when upregulated which results in the regulation of transcription of the various
Figure 12.
miRNA and bladder cancer.
Sr. no. MicroRNAs Potential targets Function Ref.
1 miR-129 TAMTA1 and EIF2CA Regulation of transcription [143]
2 miR-21 TPM1 and PTEN Growth of tumor cell [141]
3 miR-19a PTEN Increase in the cell growth [145]
Table 16.
MicroRNAs activating the bladder cancer.
Sr. no. MicroRNAs Potential targets Function Ref.
1 miR-125b E2F3 Inhibition of formation of colony and
development of cancer
[74]
2 miR-34a CD44 Inhibition of invasion, metastasis,
migration, tube formation, and angiogenesis
[146]
Table 17.
MicroRNAs suppressing the bladder cancer.
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genes in bladder cancer. Over expression of miR-34a causes the inhibition of inva-
sion, metastasis, migration, tube formation, and angiogenesis by targeting the
CD44 [146].
5.9 Glioblastoma
Glioblastoma is the tumor of astrocytes, star-shaped cells that form the support-
ive tissues (glue-like) of the brain. This is readily metastasizing tumor because it is
surrounded by large blood vessels. Glioblastoma is a complex and heterogeneous
tumor that comprises on neoplastic cells, endothelial cells, stemlike cells, neural
precursor cells, microglia, reactive extracellular components, and peripheral
immune cells [147].
The biomarker in glioblastoma is miR-21 that is upregulated in this cancer
(Figure 13). It mediates its effect in two ways: acting at the translational level and
acting at the transcription level. It binds the 30UTR region of the target gene (for
apoptosis) [148] and causes the inhibition of transcription of apoptotic genes by
decreasing the stability. It also resists the caspases 3 and 7 that are important
apoptotic agents so apoptosis does not occur [149].
Upregulation of miR-221 and miR-222 was in glioma cells. These two miRNAs
present as a cluster on Xp11.3 and have the same target. Functional studies revealed
that there is an association of these two miRNAs with the progression of the cell
cycle. Their direct target is cyclin-dependent kinase 1B/p27. The overexpression of
these miRNAs cause the activation of quiescent glioblastoma cells and the progres-
sion of these cells from G1 phase to S phase of the cell cycle. miR-221/miR-222 also
targets the p57 and p27 (inhibitors of cell-dependent kinase) to prevent the
quiescence at G1 phase and cause their entry to S phase of the cell cycle. The
miR-221/miR-222 also targets the PUMA, a proapoptotic protein, to prevent the
apoptosis (Table 18) [150].
Another biomarker miR-128 is found to be downregulated in glioblastoma.
The expression of miR-128 causes the regulation of proliferation of glioblastoma
multiform (GBM) cells via targeting the PDGFR-α and EGFR, the oncogenic kinases
Figure 13.
miRNA and glioblastoma.
Sr. no. MicroRNAs Potential targets Function Ref.
1 miR-21 Caspases 3 and 7 Antiapoptotic [149]
2 miR-221/miR-222 Cyclin-dependent kinase
1B/p27
Prevent the apoptosis [150]
Table 18.
MicroRNAs activating the glioblastoma.
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(receptor tyrosine kinases) (Table 19). It suppresses the GBM by enhancing the
differentiation of neuronal cells. It also targets the signaling molecules in the
PI3-kinase/AKT pathway which causes the tumor cell proliferation [147].
In other study miR-7 is downregulated in glioblastoma. Its target is EGFR and
causes the inhibition of AKT pathways and EGFR and results in the reduction of cell
viability of GBM via direct binding to mRNA of EGFR or via targeting to IRS1 and
IRS2 (insulin receptor substrate). The major regulators EGFR and IRS are at
upstream site of AKT pathway [151].
5.10 B cell chronic lymphocytic leukemia
This is the cancer of B lymphocytes (antibodies), and it is a prevalent form of
leukemia in the adult around western countries [152].
In B cell leukemia, the expression of three microRNAs is seen as cancer bio-
marker. These are miR-15a, miR-16-1, and miR-19a (Figure 14). Two microRNAs
are present at 13q14.3 chromosomal location; these are miR-15a and 16-1 [153]. The
expression of these two is decreased in this leukemia, whereas the expression of
miR-19a is increased [152]. The region encoding for miR-15a and miR-16-1 was
deleted. This leads to the presence of the genes of IgVH that were mutated [154].
The potent target of miR-19a is PTEN, and there is down-expression of this PTEN
gene; hence its protein is not properly synthesized because the promoter of the gene
is hypermethylated [155].
The miR-16-1 and miR-15a (located on chromosome 13) are downregulated in B
cell lymphocytic leukemia (Table 20). These miroRNAs target the p53 gene which
Sr. no. MicroRNAs Potential targets Function Ref.
1 miR-128 PDGFR-α and EGFR Enhancing the differentiation of neuronal cells [147]
2 miR-7 EGFR Reduction of cell viability [151]
Table 19.
MicroRNAs suppressing the glioblastoma.
Figure 14.
miRNA and B cell lymphocytic leukemia.
Sr. no. MicroRNAs Potential targets Function Ref.
1 miR-15a p53 Prevent the apoptosis and cell
survival is increased
[153]
2 miR-16-1 p53 Prevent the apoptosis and cell
survival is increased
[156]
Table 20.
MicroRNAs suppressing the B cell lymphocytic leukemia.
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is a tumor suppressor gene. When these miRNAs are downregulated, then the
expression of p53 is reduced or inhibited, and expression of BCL-2 is increased
which prevent the apoptosis and cell survival is increased [156].
In one study, miR-17/miR-92 cluster is overexpressed in the B cell lymphocytic
leukemia (Table 21). The direct target of this cluster is PTEN and Bim. The PTEN
is a tumor suppressor gene, and Bim is proapoptotic protein. Overexpression
of this cluster causes prevention of apoptosis and progression of tumor [157].
In other study, miR-155 is overexpressed in the B cell lymphocytic leukemia
[159]. The potential target for miR-155 is SHIP1. Expression of miR-155 causes the
alteration of BCR response in signaling pathway via the modulation of SHIP1
expression in chronic lymphocytic leukemia. Scr homology-2 domain comprising
the inositol 5-phosphatase is encoded by SHIP1. This phosphatase causes the inhi-
bition of BCR signaling and surface immunoglobulin [158].
5.11 Pancreatic cancer
Pancreatic tumor is most of the time identified at the last stages when therapy
does not save life. Li et al. characterize the pancreatic cancer stem cells (PCSCs) for
the very first time [160].
In one study, there is overexpression of miR-1290 in pancreatic cancer. The
direct target of miR-1290 is FoxA1 which has an effect on the transition of epithelial
mesenchyma. The overexpression of miR-1290 results in the growth of cell and
invasion [94].
In another study there is overexpression of miR-194 in pancreatic cancer.
The target of miR-194 is DACH1 and results in the formation of the colony, the
proliferation of cell, and migration (Table 22), so miR-194 causes the progression
of the tumor [161].
The growth and differentiation of the cell are regulated by LIN28, a protein that
binds to the RNA [162]. The protein that is encoded by LIN28 is 25 kDa and has two
binding sites for RNA: cold shock domain (CSD) and a pair of zinc fingers. In
pancreatic cancer, the expression of LIN28 is increased which in turn suppresses the
biosynthesis of family let-7 of microRNA (Figure 15). This family targets the genes
involved in the growth and differentiation regulation [163]. This LIN28 causes the
inhibition by binging to the loop present at the terminal region of let-7 family, so
Sr. no. MicroRNAs Potential targets Function Ref.
1 miR-19a PTEN Cause the tumor [155]
2 miR-17/miR-92 PTEN and Bim Prevention of apoptosis and
progression of tumor
[157]
3 miR-155 SHIP1 Inhibition of BCR signaling and
surface immunoglobulin
[158]
Table 21.
MicroRNAs activating the B cell lymphocytic leukemia.
Sr. no. MicroRNAs Potential targets Function Ref.
1 miR-1290 FoxA1 Cell growth and invasion [94]
2 miR-194 DACH1 Progression of tumor [161]
Table 22.
MicroRNAs activating the pancreatic cancer.
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their processing is blocked [45, 46, 164]. This family is involved in the regulation of
tumor by cyclin D1 (CCND1) inhibition [165, 166].
In one study there is downregulation of miR-145 in pancreatic cancer. The
decreased expression of miR-145 is due to activation of the K-ras gene. Expression
of miR-145 causes the inhibition of expression of insulin growth factor-1 receptors
(Table 23). Its expression causes the downregulation of genes related to cancer
(SET, MCM2, SPTBN1). These genes cause growth and carcinogenesis of pancreatic
cancer [161].
5.12 Acute myeloid leukemia
In the myeloid leukemia, malignant blast cells are synthesized in comparison to
mononuclear cells of healthy bone marrow [167]. In myeloid leukemia the
hypermethylation of the DNA is involved in tumor suppression [168]. In one study,
there is overexpression of miR-204 in acute myeloid leukemia. The target of
miR-204 is MEIS1 and HOXA 10 genes which disturbs the differentiation of
myeloid cells. Its overexpression causes tumorigenesis [169].
In another study, miR-125b (located on chromosome 1) is overexpressed in acute
myeloid leukemia. The target of miR-125b is BCL2-antagonist/killer 1 (Bak1) which
enhance the proliferation of AML cell and prevent the apoptosis [169].
In another study, miR-155 (located on chromosome 21) is overexpressed in the
acute myeloid leukemia. This miR-155 is located in B cell integration cluster (BIC)
gene. This BIC correlated to MYC to initiate lymphomas. Overexpression of
miR-155 causes the inhibition of WEE1, a regulator of the cell cycle, and hMLH1,
hMLH6, and hMLH4, the genes for mismatch repair (Table 24). The result of
this inhibition is increased in mutation rate in progenitor and hematopoietic stem
cells [169].
The known biomarker for the acute myeloid leukemia is miR-29b [167]. miR-
29b causes the hypomethylation of the DNA. Sp1 transcriptional factor has the
binding site for both miR-29b and DNMT1. In DNMT, it binds to its promoter and
30UTR for miR-29b of Sp1 (specificity protein 1). Binding to the 30UTR causes the
reduced expression of Sp1, so DNMT (DNA methyltransferase) expression is also
Figure 15.
miRNA and pancreatic cancer.
Sr. no. MicroRNAs Potential targets Function Ref.
1 let-7 family cyclin D1 (CCND1) Regulation of tumor [166]
2 miR-145 K-ras Growth and carcinogenesis [161]
Table 23.
MicroRNAs suppressing the pancreatic cancer.
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reduced (Figure 16). In acute myeloid leukemia, miR-29b results in the apoptosis
when it directly targets the MCL (induced myeloid leukemia cell differentiation
protein) [170]. So the expression of miR-29b is reduced in acute myeloid leukemia
which leads to cancer progression as apoptosis has been decreased with reduced
expression of miR-29b (Table 25).
5.13 Ovarian cancer
In ovarian cancer, the biomarker that is used is miR-214 and it is upregulated in
cancer. It binds to the 30UTR region of phosphatase and tensin analog (PTEN) gene
and causes its hypermethylation. So this is inactivated. The direct target of PTEN is
Akt protein kinase B and mediates its activation by the help of PI4K3B [171]. Akt
causes the downstream effects such as activation of glycogen synthase. So when
PTEN is inhibited, it activates the expression of Akt. This miR-214 resists the
cisplatin-mediated cell death, so it is antiapoptotic in nature (Figure 17). Cisplatin is
an important factor in mediating cell death [172].
In a study, there is overexpression of Hsa-miR-182 in ovarian cancer. The
potential target of Hsa-miR-182 is forkhead box 3 (FOXO3) and forkhead box 1
(FOXO1) which promote the differentiation and inhibition of growth (acting as a
tumor suppressor). These tumor suppressor genes are suppressed, and growth and
proliferation of ovarian cell are increased (Table 26) [173].
Figure 16.
miRNA and acute myeloid leukemia.
Sr. no. MicroRNAs Potential targets Function
1 miR-204 MEIS1 and HOXA Tumorigenesis
2 miR-125b Bak1 Enhance proliferation and prevent apoptosis
3 miR-155 WEE1, hMLH1, hMLH6,
and hMLH4
Increase mutation rate in progenitor and
hematopoietic stem cells
Table 24.
MicroRNAs activating the acute myeloid leukemia [169].
Sr. no. MicroRNAs Potential targets Function
1 miR-29b DNMT Apoptosis
2 miR-29b MCL protein Apoptosis
Table 25.
MicroRNAs suppressing the acute myeloid leukemia [170].
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In another study, there is downregulation of miR-200 family in ovarian cancer.
The direct target of miR-200 is zinc finger E-box-binding homeobox 1 and 2 (ZEB1
and ZEB2). It prevents the EMT, metastasis, invasion, and migration of tumor cell.
Interleukin-8 and CXCL1 (released from tumor epithelial cells) are also the target of
miR-200 and prevent the angiogenesis of tumor cell [174].
In another study there is downregulation of miR-506 in ovarian cancer, so there
is cell migration invasion of the cancer cell. When this miRNA is overexpressed, it
causes the expression of E-cadherin and results in inhibition of cell invasion and
migration and proliferation of ovarian cancer and, via targeting SNAI2 (E-cadherin
transcriptional factor), prevents the EMT induction by TGF-β (Table 27). The
miR-506 directly targets the CDK4/CDK6-FOXM1 axis and initiates the senescence
[175].
6. Conclusion
MicroRNAs (miRNAs) could be used as potential tool for early detection of
cancer. It may upregulate or downregulate multiple targets through various mech-
anisms. It is upregulated as an oncogene (miRNA) and downregulated as a tumor
suppressor. microRNA targets the PTEN, interferon (tumor suppressor genes), and
Figure 17.
miRNA and ovarian cancer.
Sr. no. MicroRNAs Potential targets Function Ref.
1 miR-214 PTEN Antiapoptosis [172]
2 Hsa-miR-182 FOXO3 and FOXO1 Increased proliferation and growth [173]
Table 26.
MicroRNAs activating the ovarian cancer.
Sr. no. MicroRNAs Potential targets Function Ref.
1 miR-200 ZEB1 and ZEB2 Prevent the EMT, metastasis, invasion, and
migration
[174]
2 miR-506 SNAI2, CDK4/
CDK6-FOXM1 axis
Inhibition of cell invasion and migration and
proliferation; initiates the senescence
[175]
Table 27.
MicroRNAs suppressing the ovarian cancer.
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also to the cell cycle along with the regulation of these genes [172]. MicroRNA is of
vital importance because of its resistance to degradation and could be a potential
candidate for clinical applications. However, its expression level can be screened in
the serum/plasma (blood) by high-throughput sequencing technology. Further
research for identification of novel microRNA will warrant the development of
microRNA-related cancer prognosis [176–180].
Abbreviations
miRISC microRNA-associated RNA-induced silencing complex
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CCND1 cyclin-D1
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MCL induced myeloid leukemia cell differentiation protein Mcl-1
PKB Akt (protein kinase B)
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